Objective:
To determine the impact of virological control on inflammation and CD4 depletion among HIV-infected children initiating antiretroviral therapy (ART) in sub-Saharan Africa.
Design:
Longitudinal cohort study.
Methods:
In a substudy of the ARROW trial (ISRCTN24791884), we measured longitudinal HIV viral loads, inflammatory biomarkers (CRP, TNF-α, IL-6, soluble CD14), and (Uganda only) whole blood immunophenotype by flow cytometry in 311 Zimbabwean and Ugandan children followed for median 3.5 years on first-line ART. We classified each viral load measurement as consistent suppression, blip/post-blip, persistent low-level VL or rebound. We used multi-level models to estimate rates of increase or decrease in laboratory markers, and Poisson regression to estimate incidence of clinical events.
Results:
Overall, 42% children experienced viral blips, but these had no significant impact on immune reconstitution or inflammation. Persistent detectable viremia occurred in one-third of children and prevented further immune reconstitution, but had little impact on inflammatory biomarkers. Virological rebound to ≥5000 copies/mL was associated with arrested immune reconstitution, rising IL-6 and increased risk of clinical disease progression.
Conclusions:
As viral load testing becomes more available in sub-Saharan Africa, repeat testing algorithms will be required to identify those with virological rebound, who need switching to prevent disease progression, whilst preventing unnecessary second-line regimen initiation in the majority of children with detectable viremia who remain at low risk of disease progression
